G5-7

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameG5-7
Drug Alias NameJAK2 inhibitor (Emory University/Harvard Medical School/University of California San Francisco)G5-7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsSignal transducer and activator of transcription 3 inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsSignal transducer and activator of transcription 3Epidermal growth factor receptor erbB1Tyrosine-protein kinase JAK2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesEmory University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoWuhan Yuanzheng Century Pharmaceutical Co LtdHarvard Medical School +[4] 
Active IndicationsN/A
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A